Literature DB >> 8272307

Postmenopausal hormone use and cholecystectomy in a large prospective study.

F Grodstein1, G A Colditz, M J Stampfer.   

Abstract

OBJECTIVE: To examine the association between postmenopausal hormone use and cholecystectomy.
METHODS: A prospective cohort study was performed, with follow-up every 2 years. Participants were 54,845 postmenopausal United States nurses, who reported both hormone use and cholecystectomy on mailed questionnaires.
RESULTS: Cholecystectomy was reported by 1750 women during 8 years of follow-up. After adjusting for confounding factors, women currently using postmenopausal hormones were at an increased risk of cholecystectomy (relative risk [RR] 2.1, 95% confidence interval [CI] 1.9-2.4) compared to never-users. For current users, the risk of cholecystectomy increased with increasing duration of hormone use (RR 2.6, 95% CI 2.2-3.1 for 10 years or more) and higher doses of estrogen (RR 2.4, 95% CI 2.0-2.9 for users of 1.25 mg or more). Although the risk for past hormone users decreased substantially in women who had discontinued use 1-2.9 years ago (RR 1.6, 95% CI 1.2-2.0), a small risk persisted for women who had stopped taking hormones 5 or more years previously (RR 1.3, 95% CI 1.1-1.6). However, after controlling for time since last use, duration of past use had little or no effect on the risk of cholecystectomy (RR 1.4 and RR 1.7 for past users of less than 2 years and 10 or more years' duration, respectively).
CONCLUSION: Women using postmenopausal hormones are at an increased risk of cholecystectomy. Women and their physicians should consider the spectrum of risks and benefits when deciding whether to take hormones.

Entities:  

Mesh:

Year:  1994        PMID: 8272307

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  22 in total

1.  Postmenopausal estrogen replacement therapy and increased rates of cholecystectomy and appendectomy.

Authors:  M M Mamdani; K Tu; C van Walraven; P C Austin; C D Naylor
Journal:  CMAJ       Date:  2000-05-16       Impact factor: 8.262

2.  Hormone replacement therapy for the primary prevention of chronic diseases: recommendation statement from the Canadian Task Force on Preventive Health Care.

Authors:  C Nadine Wathen; Denice S Feig; John W Feightner; Beth L Abramson; Angela M Cheung
Journal:  CMAJ       Date:  2004-05-11       Impact factor: 8.262

3.  Postmenopausal estrogen therapy and risk of gallstone disease: a population-based case-control study.

Authors:  Maja Hellfritzsch Simonsen; Rune Erichsen; Trine Frøslev; Jørgen Rungby; Henrik Toft Sørensen
Journal:  Drug Saf       Date:  2013-12       Impact factor: 5.606

Review 4.  Hormone replacement therapy: II. A pharmacoeconomic appraisal of its role in the prevention of postmenopausal osteoporosis and ischaemic heart disease.

Authors:  R Whittington; D Faulds
Journal:  Pharmacoeconomics       Date:  1994-06       Impact factor: 4.981

5.  Ospemifene and 4-hydroxyospemifene effectively prevent and treat breast cancer in the MTag.Tg transgenic mouse model.

Authors:  Rebekah A Burich; Neelima Rakesh Mehta; Gregory T Wurz; Jamie Lee McCall; Brittany E Greenberg; Katie E Bell; Stephen M Griffey; Michael W DeGregorio
Journal:  Menopause       Date:  2012-01       Impact factor: 2.953

Review 6.  Postmenopausal hormone therapy: an Endocrine Society scientific statement.

Authors:  Richard J Santen; D Craig Allred; Stacy P Ardoin; David F Archer; Norman Boyd; Glenn D Braunstein; Henry G Burger; Graham A Colditz; Susan R Davis; Marco Gambacciani; Barbara A Gower; Victor W Henderson; Wael N Jarjour; Richard H Karas; Michael Kleerekoper; Roger A Lobo; JoAnn E Manson; Jo Marsden; Kathryn A Martin; Lisa Martin; JoAnn V Pinkerton; David R Rubinow; Helena Teede; Diane M Thiboutot; Wulf H Utian
Journal:  J Clin Endocrinol Metab       Date:  2010-06-21       Impact factor: 5.958

7.  Alterations in gallbladder emptying and bile retention in the absence of changes in bile lithogenicity in postmenopausal women on hormone replacement therapy.

Authors:  Radha K Dhiman; Pralay K Sarkar; Arpita Sharma; Kala Vasishta; Krishan K Kohli; Sanjay Gupta; Sudha Suri; Yogesh Chawla
Journal:  Dig Dis Sci       Date:  2004-08       Impact factor: 3.199

8.  Use of hormone replacement therapy and the risk of colorectal cancer.

Authors:  Gad Rennert; Hedy S Rennert; Mila Pinchev; Ofer Lavie; Stephen B Gruber
Journal:  J Clin Oncol       Date:  2009-08-24       Impact factor: 44.544

Review 9.  Risks and benefits of hormone replacement therapy: the evidence speaks.

Authors:  Karin H Humphries; Sabrina Gill
Journal:  CMAJ       Date:  2003-04-15       Impact factor: 8.262

10.  Menopausal hormone therapy and risk of cholecystectomy: a prospective study based on the French E3N cohort.

Authors:  Antoine Racine; Anne Bijon; Agnès Fournier; Sylvie Mesrine; Françoise Clavel-Chapelon; Franck Carbonnel; Marie-Christine Boutron-Ruault
Journal:  CMAJ       Date:  2013-03-18       Impact factor: 8.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.